drugset / Trial / NCT01483924
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-08
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORILOTIMOD | Small molecule | 10 mg | — |
| Subject | ORILOTIMOD | Small molecule | 30 mg | — |
| Subject | ORILOTIMOD | Small molecule | 60 mg | — |
| Subject | ORILOTIMOD | Small molecule | 100 mg | — |